Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Retuxira with CHOP vs CHOP followed by Retuxira Maintenance in DLBCL
NCT01459887Phase 3Completed
- Sponsor
- 3S Guojian Pharmaceutical
- Start
- Sep 2006
- Primary completion
- Dec 2010
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of 304 injection in diffuse large B-cell lymphoma (DLBCL) (2 arms), sponsored by 3S Guojian Pharmaceutical. Primary endpoint: Overall Response Rate at 18 weeks. Started Sep 2006; status: completed.
02
Drugs
304 injection
03
Conditions
diffuse large B-cell lymphoma (DLBCL)
Beyond the preview
Go deeper on NCT01459887.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01459887.